We recently demonstrated that knockdown of PSMD1 and PSMD3 resulted in increased apoptosis of CML cells but not normal cord blood controls, implicating they may be good targets for therapy [31]. This evidence concerns the gene PSMD3 and chronic myelogenous leukemia, BCR-ABL1 positive.